Basics Innoviva, Inc. Innoviva Inc is a biopharmaceutical company that is engaged in the discovery, development and commercialization of small molecule medicines. The firm collaborates with and receives funding from GlaxoSmithKline. IPO Date: November 25, 2008 Sector: Healthcare Industry: Pharma Market Cap: $1.55B Activated in VL: True Average Daily Range Avg Daily Range: $0.20 | 1.45% Avg Daily Range (30 D): $0.25 | 1.26% Avg Daily Range (90 D): $0.25 | 1.31% Institutional Daily Volume Avg Daily Volume: .64M Avg Daily Volume (30 D): .62M Avg Daily Volume (90 D): .6M Trade Size Avg Trade Size (Sh.): 94 Avg Trade Size (Sh.) (30 D): 49 Avg Trade Size (Sh.) (90 D): 50 Institutional Trades Total Inst.Trades: 4,365 Avg Inst. Trade: $1.77M Avg Inst. Trade (30 D): $2.7M Avg Inst. Trade (90 D): $2.32M Avg Inst. Trade Volume: .12M Avg Inst. Trades (Per Day): 1 Market Closing Trades Avg Closing Trade: $1.81M Avg Closing Trade (30 D): $3.27M Avg Closing Trade (90 D): $2.88M Avg Closing Volume: 121.32K     News Aug 7, 2025 @ 3:17 AM Innoviva (INVA) Q2 Sales Jump 64% Source: Na Dec 16, 2024 @ 6:15 AM Basilea announces agreement with Innoviva Specialt... Source: N/A Jun 18, 2024 @ 5:44 PM Analyst Projects Strong Growth for GSK-Innoviva Pa... Source: Vandana Singh Mar 2, 2024 @ 3:29 PM 10 stocks you can bet on being inflation-proof Source: MarketWatch May 24, 2023 @ 2:32 AM FDA approves Innoviva’s bacterial pneumonia... Source: MarketWatch Financials   TTM Q3 2025 Q2 2025 Basic EPS $1.97 $1.3 $1.01 Diluted EPS $1.66 $1.08 $.77 Revenue $ 388.52M $ 107.8M $ 100.28M Gross Profit $ $ 75.54M $ 83.15M Net Income / Loss $ 127.34M $ 89.91M $ 63.69M Operating Income / Loss $ 38.42M $ 34.58M $ 48.75M Cost of Revenue $ $ 32.26M $ 17.14M Net Cash Flow $ 215.88M $ 78.98M $ 78.44M PE Ratio 12.71     Splits Jun 17, 2013:   1:100